Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants

Phase 1 Active not recruiting 32 enrolled Suzhou Ribo Life Science Co. Ltd.

RandomizedSequentialSingle-blindTreatment

Summary

This is a Randomized, Single-blind, Placebo-Controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD1119 in Healthy Participants.

Timeline

Start: 2025-08-26
Primary completion: 2026-06
Completion: 2026-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RBD1119	Unknown	—	Subcutaneous

Indications

No indication recorded.